EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Reduced prophylactic effect of tixagevimab–cilgavimab in patients with hematological malignancies and without antibody response after SARS‐COV‐2 vaccination

Chiara Callegari iD, Davide Lazzarotto, Alessandra Soravia, Martina Mutti, Pietro Lauzzana, Maddalena Peghin, Stefano Cordella, Renato Fanin, Anna Candoni

European Journal of Haematology · 2023

DOI: 10.1111/ejh.14045 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Chiara Callegari und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Stem Cell Transplantation Unit, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy. Hauptthemen laut MEDLINE: COVID-19, Hematologic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Hematologic NeoplasmsHumansAntibody FormationCOVID-19 VaccinesSARS-CoV-2VaccinationAntibodies, Monoclonal

Substanzen

COVID-19 VaccinestixagevimabAntibodies, Monoclonalcilgavimab

Autor:innen und Institutionen

  • Division of Hematology and Stem Cell Transplantation Unit, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
  • Division of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Division of Infectious Diseases, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.

ORCID-Profile: Chiara Callegari

Zitieren

APA

Callegari, C., Lazzarotto, D., Soravia, A., Mutti, M., Lauzzana, P., Peghin, M., Cordella, S., Fanin, R., & Candoni, A. (2023). Reduced prophylactic effect of tixagevimab–cilgavimab in patients with hematological malignancies and without antibody response after SARS‐COV‐2 vaccination. European Journal of Haematology. https://doi.org/10.1111/ejh.14045

Vancouver

Callegari C, Lazzarotto D, Soravia A, Mutti M, Lauzzana P, Peghin M, et al. Reduced prophylactic effect of tixagevimab–cilgavimab in patients with hematological malignancies and without antibody response after SARS‐COV‐2 vaccination. European Journal of Haematology. 2023. doi:10.1111/ejh.14045

BibTeX
@article{Callegari2023,
  author = {Callegari, Chiara and Lazzarotto, Davide and Soravia, Alessandra and Mutti, Martina and Lauzzana, Pietro and Peghin, Maddalena and Cordella, Stefano and Fanin, Renato and Candoni, Anna},
  title = {Reduced prophylactic effect of tixagevimab–cilgavimab in patients with hematological malignancies and without antibody response after SARS‐COV‐2 vaccination},
  journal = {European Journal of Haematology},
  year = {2023},
  doi = {10.1111/ejh.14045}
}
Kostenlos starten →